Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source

Source document· January 12, 2026

Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight

View original at globenewswire.com

Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight New York, USA, Jan…

Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

In 2024, the total diagnosed prevalent cases of ASCVD across the 7MM were approximately 65 million, and this burden is projected to rise over the forecast period
80% confidence
While marketed therapies have cemented PCSK9 inhibition as a powerful intervention, uptake challenges have left room for innovation. This gap is now fueling a new wave of competition with oral, long-acting, and gene-editing approaches.
80% confidence
The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025-2034) at a CAGR of 4.9%
80% confidence
In the United States, systemic inflammation-associated ASCVD cases were estimated at approximately 17 million in 2024
80% confidence
The ASCVD clinical trial landscape is undergoing a notable transition, moving beyond traditional LDL-C-focused strategies toward more targeted, mechanism-based interventions for cardiovascular risk reduction
80% confidence
The market size for atherosclerotic cardiovascular disease was USD 23 billion in the leading markets in 2024
80% confidence
Despite strong clinical validation, real-world adoption challenges for existing PCSK9 inhibitors have opened the door to next-generation therapies
80% confidence
The dynamics of the ASCVD market are expected to change in the coming years due to the launch of emerging therapies
80% confidence
The advancement of late-stage candidates such as Amgen's olpasiran and Ionis/Novartis' pelacarsen highlights the increasing clinical and commercial emphasis on lipoprotein(a), a genetically determined and long-overlooked contributor to residual ASCVD risk
80% confidence
The United States accounted for approximately 75% of the total ASCVD market size in the 7MM in 2024
80% confidence